Buy Docetaxel (Taxotere) online

Price: 2,012 UAH

Known as original brand(s)

Taxotere

Buy Docetaxel (Taxotere) online with delivery. Browse medicines that contain Docetaxel, compare doses and prices.

Docetaxel is a potent antineoplastic agent belonging to the taxane class of plant alkaloids, originally marketed under the brand name Taxotere. It is widely utilized in medical oncology to treat various solid tumors, including breast, lung, prostate, gastric, and head and neck cancers.

The mechanism of action of docetaxel involves promoting the assembly of tubulin into stable microtubules and inhibiting their disassembly. This leads to a significant decrease in free tubulin, disruption of the mitotic spindle formation, and cell cycle arrest at the M and G2 phases, ultimately inducing apoptotic cell death in cancer cells.

Clinical administration of docetaxel significantly inhibits tumor growth and progression, extends overall survival, and reduces relapse rates in both adjuvant and metastatic treatment settings.

Wikipedia page
Docetaxel (Taxotere)

Indications

Docetaxel is indicated in medical oncology for the treatment of the following conditions:

  • Breast Cancer: Locally advanced or metastatic breast cancer, as well as adjuvant treatment of node-positive operable breast cancer.
  • Non-Small Cell Lung Cancer (NSCLC): Locally advanced or metastatic NSCLC after failure of prior chemotherapy, or first-line in combination with cisplatin.
  • Prostate Cancer: Metastatic castration-resistant prostate cancer (administered with prednisone).
  • Gastric Adenocarcinoma: Metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma (in combination with cisplatin and fluorouracil).
  • Head and Neck Cancer: Induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

Dosage and administration

Docetaxel is administered strictly as an intravenous infusion in a clinical oncology setting:

  • Recommended Dosage: Standard dosage ranges from 75 mg/m² to 100 mg/m² administered as a 1-hour intravenous infusion every 3 weeks (21 days). Weekly schedules (e.g., 35 mg/m²) may also be utilized.
  • Premedication (Mandatory): To reduce the incidence and severity of fluid retention and hypersensitivity reactions, all patients must be premedicated with oral corticosteroids (e.g., dexamethasone 8 mg twice daily) for 3 days, starting 1 day prior to docetaxel administration.
  • Administration Technique: Administered IV over 1 hour following dilution in 0.9% sodium chloride or 5% dextrose solution.
  • Monitoring: Complete blood counts (neutrophil and platelet levels) and liver function tests must be monitored prior to each cycle.

Docetaxel is contraindicated in the following cases:

  • Severe Neutropenia: Baseline neutrophil counts less than 1,500 cells/mm³.
  • Hepatic Impairment: Severe hepatic dysfunction (elevated bilirubin, ALT/AST, or alkaline phosphatase).
  • Hypersensitivity: Severe hypersensitivity to docetaxel or polysorbate 80 (excipient).
  • Pregnancy and Lactation: Pregnancy and breastfeeding periods due to potential embryofetal toxicity.

Treatment with docetaxel may cause the following adverse reactions:

  • Hematologic: Neutropenia (including febrile neutropenia), anemia, and thrombocytopenia.
  • Hypersensitivity Reactions: Flushing, skin rash, bronchospasm, and hypotension.
  • Fluid Retention: Peripheral edema, pleural effusion, pericardial effusion, and ascites.
  • Dermatologic: Alopecia, nail changes (hyperpigmentation or onycolysis), and skin reactions.
  • Gastrointestinal: Nausea, vomiting, diarrhea, and stomatitis.
  • Nervous System: Peripheral neuropathy (paresthesia, numbness, or dysesthesia).
  • Musculoskeletal: Myalgia and arthralgia.

Frequently Asked Questions

Docetaxel is a semisynthetic antineoplastic agent belonging to the taxane class. Its primary mechanism of action involves binding to free tubulin and promoting its assembly into stable microtubules while simultaneously inhibiting their disassembly. This leads to the stabilization of microtubules and disrupts normal cell division during the M-phase of the cell cycle, ultimately halting tumor cell proliferation and initiating programmed cell death (apoptosis).
Docetaxel is widely indicated for the treatment of several solid tumors across various clinical stages. Its principal indications include locally advanced or metastatic breast cancer, non-small cell lung cancer, metastatic castration-resistant prostate cancer, gastric adenocarcinoma, and squamous cell carcinoma of the head and neck. It can be administered as monotherapy or in combination regimens with other chemotherapeutic or targeted agents.
Premedication with oral corticosteroids, such as dexamethasone, is a mandatory risk-mitigation step prior to intravenous docetaxel infusion. Patients typically begin taking dexamethasone the day before therapy and continue for 1 to 2 days post-infusion. This regimen is critical to reduce the incidence and severity of acute hypersensitivity reactions and to prevent cumulative fluid retention, which commonly manifests as peripheral edema, pleural effusion, or pericardial effusion.
Docetaxel is administered strictly as a 1-hour intravenous infusion under continuous clinical supervision in an outpatient infusion suite or hospital ward. Vital signs are monitored closely during administration to detect early manifestations of hypersensitivity, such as bronchospasm, hypotension, or urticaria. Local tissue reactions, including hyperpigmentation, inflammation, or phlebitis, can occur at the injection site, requiring proper care for venous access during administration.
The primary dose-limiting toxicity of docetaxel is myelosuppression, specifically severe neutropenia, which elevates the risk of febrile infections. Complete blood counts are mandatory prior to each cycle; if neutrophil counts drop below safety thresholds, dosing must be delayed or reduced. Other frequent adverse events include complete alopecia, systemic fatigue, peripheral sensory neuropathy (numbness or tingling in the extremities), nail changes, stomatitis, and gastrointestinal distress.

Medicines containing Docetaxel

-18%
Docelieva RTU
View
Allieva

Docelieva RTU

Docetaxel
80 mg 1 vial
2012₴ 2459₴
✅ All products loaded (1)

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00